Introduction
============

Circular RNAs (circRNAs) were first discovered by scientists when using electron microscope to observe RNA virus in the 1970s[@B1]. Nevertheless, due to the technique limitations, circRNAs were originally considered as by-products of mRNA error splicing, occupying minimal amount in cells[@B2]. With the development and progress of scientific technologies, especially the appearance of high-throughput sequencing and bio-informatics, mounting circRNA families have been found in prokaryotes, animals, plants, and humans[@B3]-[@B6]. As non-coding RNA (ncRNA) with neither 3\'-5\'end polarity nor polynucleotide tails, it was revealed in many researches that circRNAs play essential roles in tumorgenesis and development[@B7].

Until now, a few of review articles had been previously published to elucidate the potential relationship between circRNAs and cancer. But most of them were tried to study the associated of circRNAs and the overall cancer. Compared to those of previous studies, we focused on the relationship between circRNAs and gastric cancer which is the fifth common cancer and the third major cause of cancer death worldwide [@B8]. We aim to explore the relationships between circRNAs and GC by briefly describing the biological characteristics, process of synthesis and scavenging, classification and function of circRNAs; comprehensively summarizing the correlations of circRNAs with biological behaviors of GC cells and clinicopathological features of GC patients; and systematically reviewing the applications of circRNAs as biomarkers in prediction, diagnosis, treatment and prognosis of GC (Figure [1](#F1){ref-type="fig"}).

Biological characteristics of circRNAs
======================================

On account of the unique circular structure, circRNAs vary from linear RNAs in several characteristics, which are the preconditions of being biomarkers for disease. The characteristics of circRNAs are as follow: Ⅰ. Strong stability: CircRNA is a covalently closed loop structure without 3\'/5\' end polarity and polynucleotide tail. Therefore, circRNA cannot be affected by ribonuclease R and RNA nucleic acid exonuclease[@B7]. Ⅱ. Abundant content: Owing to its strong stability and relative long half-life period, circRNA is 10 times richer than corresponding linear RNAs in cells and is also abundant in extracellular fluid[@B3], [@B5]. Thus, the expression levels of circRNAs in tissues at present can be detected by real-time fluorescent quantitative PCR experiment. Besides, owing to the specific and stable characteristics of circRNAs, their expression levels can also be detected in plasma, saliva and urine. Therefore, circRNAs can be regarded as promising biomarkers for diagnosis and prognosis assessment of diseases[@B9]-[@B12]. Ⅲ. Specific expression: Tissue- or developmental stage- specific expressions of circRNAs can frequently be observed in the same organism, and the specificity also exist among different species[@B3], [@B13]. Hence, circRNA as normal dynamic balanced product of gene and a member of regulatory pathway in cells, participates in the development of diseases and may act as specific target for the disease treatment.

Synthesis and removal of circRNAs
=================================

The homeostasis of circRNAs in cells are attributed to their specific biosynthesis and scavenging mechanisms. Firstly, for the coding genes of circRNAs, most of their gene sequences are located in exon regions of host genes, and others are located in introns or intergenic regions[@B3], [@B5], [@B14]. Some exons can transcribe multiple circRNAs [@B3], [@B14]. Secondly, regarding the biosynthesis patterns of circRNAs, back-splicing pattern is the most widely recognized one. The majority of circRNAs are synthesized at the post-transcriptional level through pre-mRNA back-splicing [@B15], [@B16]. During the back-splicing process, the 5\' and the 3\' end splicing site form a covalent closed ring by 3\'-5\'phosphodiester bond[@B7], [@B14]. CircRNAs are synthesized by back-splicing at a very slow pace under natural condition, however, the biosynthetic speed can be affected by multiple factors including the competitions of pre-mRNA splicing, the distances between RNA binding protein (RBP) -induced splicing sites, the extension rates of RNA rapid polymerase Ⅱ, the controls of cis-acting elements *in vivo* and the self positive feedback, etc [@B15], [@B17]-[@B19]. Besides, the known mechanism for circRNAs scavenging is that the intracellular circRNA can be excreted out of cells through the extracellular vesicles (EVs). Then, part of the EVs rupture and release the circRNAs into extracellular fluid; another part are absorbed by other cells along with encapsulated circRNAs[@B20].

Categories and function of circRNAs
===================================

Based on the coding genes, tens of thousands of circRNAs are divided into different subtypes, which are as follows. Ⅰ. exon circRNAs (ecircRNAs), generated from exons[@B3]. Ⅱ. intron circRNAs (ciRNAs), generated from introns[@B3], [@B21]. Ⅲ. exon and intron circRNAs (EIciRNAs), generated from both exons and introns[@B22]. Ⅳ. fusion circRNA (f-circRNAs), generated from cancer-associated chromosomal translocations[@B23]. EcircRNAs are enriched in cytoplasm, while ciRNAs and EIciRNAs are distributed in cytoplasm with less amount [@B3], [@B21], [@B24]. With in-depth researches, the biological functions of circRNAs gradually emerge and researches revealed that subtypes of circRNAs were not only distinct in cellular localizations, but also in biological functions. Firstly, circRNAs can function as natural sponge of miRNAs. In cytoplasma, ecircRNAs as the sponge of miRNAs, restrain miRNAs functions, thus regulating the expressions of target mRNAs[@B4], [@B25]. In nucleus, ciRNAs may act as the sponge of protein, influencing cell function[@B17], [@B26]. Secondly, ciRNAs and EIciRNAs can activate or positively regulate the transcriptions of parental genes in the nucleus[@B21], [@B24]. Thirdly, as mentioned above, some cells can transport circRNAs out of cells via EVs and then were acquired by other cells through intaking these EVs, which means circRNAs may contribute to the cell communications[@B20]. Fourthly, latest research elucidated that intracellular circRNAs can be used as templates for protein translations. Fifthly, in cells, when the circRNAs sequence contains the m6A sequence, translation can be performed and the changes of m6A expression level affect the efficiency of this process[@B27], [@B28].

Interactive network of circRNAs with other non-coding RNA and proteins
======================================================================

CircRNAs can form regulatory pathways with other biomolecules in cells with miRNAs, siRNAs, lncRNAs and proteins through various different ways. Ⅰ, circRNAs could form a regulatory pathway with the small size non-coding RNA, miRNAs[@B4]. Hansen, TB and his team demonstrated that the target sites of miR-7 exist on ciRS-7 and the ciRS-7 can more effectively inhibit miR-7, comparing with traditional anti-miRNA methods[@B4]. Deserved to be mentioned, this is the first circRNA-miRNA regulatory pathway be discovered. Subsequently, scientists also revealed this ciRS-7-miR-7 co-expression pathway when they researched other miR-7 related physiological and pathological processes in the human diseases including insulin secretion, tumor, neurodegenerative diseases, intervertebral disc degeneration, systemic lupus erythematosus, etc[@B29]-[@B33]. Coexpression of ciRS-7-miR-7 was also found in the brains of different animals and plants[@B34]-[@B36]. Therefore, this circRNA-miRNA regulatory pathway not only extensively exist in nature, but also is a diversified regulatory pathway that regulates many physiological and pathological processes[@B34]-[@B36]. A miRNA may be controlled by multiple circRNAs, and a circRNA can also suppress the various miRNAs at the same time[@B4], [@B37]-[@B39]. CircRNAs can not only inhibit the function of miRNAs through the ceRNAs (competing endogenous RNAs) network mechanism to form regulatory pathways, but also affect cell function by stabilizing the miRNAs activities[@B40]. Ⅱ. circRNAs could form a regulatory pathway with other non-coding RNAs including small interfering RNA (siRNA) and long non-coding RNA (lncRNA). SiRNAs can infiltrate into \'RNA induced silencing complex\' (RISC), leading to RNA interfere (RNAi), and then specifically inhibit the functions of circRNAs by binding with circRNAs[@B41], [@B42]. LncRNA or pseudogenes can inhibit the functions of miRNAs, and have synergistic effects with circRNAs [@B37], [@B43], [@B44]. Transcription factors facilitate circRNA expressions by binding to promoters[@B45]. Ⅲ, circRNAs could form a regulatory pathway with proteins. The circRNAs can be the templates for mRNA translation, which impact on protein expression level directly, forming the circRNAs and proteins regulatory pathways[@B27], [@B28]. The regulatory pathways of circRNAs and proteins are found to be carried out in three ways. The first one is to regulate the translations of mRNAs indirectly by regulating the circRNA-miRNA pathways, thus affecting the synthesis of proteins[@B46], [@B47] . CircRNA inhibits miRNA function and removes the inhibition of miRNA on mRNA, thus increasing protein content [@B48], [@B49]. For example, in cells, circRNA_001569 regulates NR4A2 mRNA by acting with miR-145[@B50]. The second one is acting as RNA binding proteins (RBP) sponge, competitive binding with RBP, consequently influencing mRNA translation[@B51]. Both co-expressions of circRNA and RBP in the nucleus (such as circRNA MBL and MBL and ci-ankrd52 and POlII) and complexes formed by circRNAs and proteins in the cytoplasm are evidences of this molecular network[@B17], [@B21], [@B52]. Ⅳ. The above-mentioned three pattern could also function with each other which could compose of a network. A regulatory pattern that "circRNA-miRNA-mRNA" or "circRNA-miRNA-lncRNA" had been studied which were a ceRNA network[@B4], [@B53]. In summarized, circRNAs could form regulatory pathway with miRNAs, siRNAs, lncRNAs and proteins and then composed an interactive network.

CircRNAs involving in the regulations the biological behaviors of gastric cancer cells
======================================================================================

Recent researches demonstrated that the expression level of circRNAs is closely related to the biological behavior of GC cells[@B54], [@B55]. A study regarding GC conducted by Li,J, et al showed that circ_104916 had tumor inhibition effect, correlated with the proliferation, invasion, migration and epithelial mesenchymal transition (EMT) of GC cells[@B56]. In comparison with normal gastric tissues and GES-1 cell lines, the expression levels of circ_104916 in GC tissues and five GC cell lines were down-regulated[@B56]. And further *in vitro* experiments elucidated that circ_104916 could inhibit the proliferation, invasion, migration and the EMT process of GC cells[@B56]. Similarly, Zhang,J et al. found that the expression of circLARP4 in GC tissues was down-regulated compared with normal gastric tissues. circLARP4 could relieve the mRNA LATS1 inhibition by inhibiting the miR-424 function, hence affecting the proliferation and invasion of GC cells[@B57]. In this study, researchers first discovered that miR-424 had LATS1 binding site, facilitating the proliferation and invasion of GC cells by inhibiting the expressions of LATS1[@B57]. Through prediction of bioinformatics, data analysis of circRNA expression profiles and the verification of luciferase reporter assay and RNA immunoprecipitation (RIP), they came to conclusion that the circLARP4 can serve as a sponge for miR-424[@B57]. Further experiments were designed to explore the effects of circLARP4 on the biological behaviors of GC cells and found that overexpression of circLARP4 inhibited the proliferation and invasion of GC cells, while down-regulation of circLARP4 promoted these processes[@B57]. Although these studies focused on different circRNAs, they all demonstrated that the GC tissue differently expressed circRNAs were intimately related to the biological behaviors of GC cells and might play vital roles in the pathogenesis and development of GC[@B58], [@B59]. Thus far, still numerous circRNAs are unconfirmed, and more mechanisms concerning the impact of circRNAs on biological behaviors of GC cells remain to be explored. Association between circRNAs and gastric cancer cells biological behavior in previous studies is shown in Table [1](#T1){ref-type="table"}.

Correlation between circRNA expression and clinicopathological features of patients with gastric cancer
=======================================================================================================

In recent years, as the circRNAs researches progressed, relationships between circRNAs and human diseases have gradually emerged. Through in-depth analyses and comparisons of circRNAs expression profiles in different diseases, it has become an indisputable fact that circRNAs can present different expression profiles in different diseases. Currently, many researches have listed out the expression profiles of circRNAs in GC[@B60]. Comparing the GC tissues with adjacent tissues through microarray technique, Sui,W et al. discovered 1285 differentially expressed circRNAs [@B61]. Moreover, Dang,Y. et al\'s research reported the circRNAs expression profiles using five GC tissues and five matched non-cancer tissues with circRNA chip technique, and revealed that totally 713 circRNAs (191 up-regulated and 522 down-regulated) were differentially expressed[@B62]. In spite of the results of circRNAs expression profiles obtained by different experimental techniques were distinct, they indicated that masses of circRNAs expression levels changed during the development of GC[@B63]-[@B65].

A study based on the results of microarray screening and qRT-PCR assay reported that the expression of hsa_circ_0000190 in GC tissues was down-regulated compared with that in adjacent normal tissues[@B66]. To assess the diagnostic value of hsa_circ_0000190, they generated a receiver operating characteristic (ROC) curve, observing that areas under the curve (AUC) were 0.60 and 0.75 in plasma and tissue, respectively. Moreover, the AUC, sensitivity and specificity of the combined group (combining plasma hsa_circ_0000190 and tissue hsa_circ_0000190) were 0.775, 0.712 and 0.750, respectively[@B66]. Further analyzing the association of hsa_circ_0000190 expression levels in GC tissue and plasma with the clinicopathological features of 104 GC patients, we discovered that the hsa_circ_0000190 expression levels were not only related to tumor size, lymph node metastasis and CA19-9 level, but also significantly correlated with CEA level, distal metastasis and TNM stage[@B66]. Results indicated that higher hsa_circ_0000190 levels in tissue were observed in GC patients with large tumor diameter (d≥5), no lymph node metastasis, no distant metastasis, low TNM stage and CA19-9 negative, while CEA positive patients had a higher hsa_circ_0000190 levels in plasma[@B66].

Another research revealed that hsa_circ_0001895 was also correlated with clinicopathological features of GC patients[@B67]. By analyzing the relationships between the clinicopathological features of 96 GC patients and hsa_circ_0001895 expression level in GC tissues, Shao,Y et al, found that the expression level of hsa_circ_0001895 was high in patients with well differentiation, Borrmann grade III and IV, and GEA positive expression[@B67].

Furthermore, Lu,R et al concerned with hsa_circ_0006633, detecting its expression level in GC cell line, tissue and plasma through qRT-PCR method and discovered it could act as a tumor suppressor molecule[@B68]. In healthy tissues, the expression of hsa_circ_0006633 was significantly higher than that in gastritis and atypical hyperplasia tissues, and it was significantly higher in paracancerous tissues than in GC tissues. Concerning the relationships between the expression level of hsa_circ_0006633 and clinicopathological features in 96 patients with GC, they elucidated that patients without distant metastasis and CEA positive patients had statistically higher expression level of hsa_circ_0006633[@B68].

It will contribute to identifying novel molecules involved in the GC development by analyzing the correlations of differentially expressed circRNAs with the clinicopathological features of patients with GC and helps us in better recognizing the progression of GC.

CircRNAs can be used as a marker for early diagnosis of gastric cancer
======================================================================

CircRNAs can potentially be biomarkers for clinical disease diagnosis due to their more stable structure and longer half-life than linear RNAs, better abundance and high specificity. Of note, circRNAs in extracellular fluid (such as saliva and plasma) released through EVs and cell lysis are also abundant and specific, making circRNAs potentially useful as non-invasive biomarkers for clinical disease diagnosis. For GC patients, circRNAs in their tissues and plasma are expected to be biomarkers for early diagnosis of GC [@B12], [@B69], [@B70].

For hsa_circ_002059, researchers suggested that it was significantly down-regulated in GC tissues and was correlated with distant metastasis and TNM stages through detecting 96 pairs of GC tissues and their corresponding normal gastric tissues by using qRT-PCR method[@B71]. Moreover, as a diagnostic marker for GC, the AUC of hsa_circ_002059 was 0.73, and the sensitivity, specificity and cut-off value were 0.81, 0.62 and 12.9, respectively[@B71]. Another research performed by Zhao Q. et al used qRT-PCR method to observe the expression level of hsa_circ_0000181 and indicated that it was significantly down-regulated in GC tissues and plasma of GC patients than in paired normal tissues and healthy people[@B72]. Additionally, analyses on its diagnostic value showed that the hsa_circ_0000181 level in GC tissue and plasma could act respectively as invasive and non-invasive biomarker for diagnosing GC[@B72]. Observing the diagnostic ability of hsa_circ_0000181 in GC tissues and in plasma samples, we found that the specificity of tissue specimens was 0.852 which was significantly higher than that of plasma samples 0.206; the sensitivity of tissue specimens was 0.539 while sensitivity of plasma samples was 0.990[@B72]. Therefore, plasma circRNAs, as diagnostic biomarkers, have advantages over tissue circRNAs in its non-invasiveness and better diagnostic ability for early GC.

In conclusion, the sensitivities of hsa_circ_002059 detected in both tissue samples and plasma samples meet the requirements of the diagnosis biomarker for GC[@B71]. CircRNAs have vast application prospect in non-invasive diagnosis and early diagnosis of GC. The diagnostic efficiency of circRNAs as a biomarker for gastric cancer is shown in Table [2](#T2){ref-type="table"}.

CircRNAs provide new specific targets for the treatment of gastric cancer
=========================================================================

Recently, as digging deeper into the circRNAs, researchers have a heightened awareness of their functions. Up-regulated or down-regulated circRNAs may be novel specific therapeutic targets for GC with different phenotypes, invasion or metastasis ability, improving the survival rate of patients with GC.

Firstly, circRNAs can regulate the malignant phenotype related signaling pathway of GC through some specific functions. Hence, regulating the level of circRNAs may steer GC cells into a better condition. CiRS-7, as the firstly discovered circRNA with miRNA sponge function represses the miR-7 function in GC tissues[@B73]. Up-regulated ciRS-7 regulates the PTEN/PI3K/AKT pathway by suppressing miR-7, consequently affecting the apoptosis and migration of GC cells[@B73]. In addition, down-regulated hsa_circ_0000096 in GC tissues can impact the proliferation and migration of GC cells by modulating cyclin D1, CDK6, MMP-2 and MMP-9[@B74]. Inhibited hsa_circ_0000096 significantly suppress the proliferation and migration of GC cells[@B74]. Besides, inhibition of hsa_circ_0047905, hsa_circ_0138960 and hsa_circRNA7690-15 not only down-regulates the expressions of maternal genes, but also represses the proliferation and invasion of GC cells, discovered in another study on GC [@B75]. Based on these reported findings, researchers suggest that the inhibited intracellular circRNAs result in suppressed proliferation and invasion abilities of GC cells, thus attaining a better phenotype of GC. This phenomenon can also be observed in animals. For instance, the growth rate of mice injected with miR-7 over-expressed tumor cells is lower than that of mice injected with ciRS-7 over-expressed tumor cells. The inhibition of hsa_circ_0000096 in nude mice can induce the decrease of Ki67 and VEGF.

Secondly, EVs make it possible for circRNAs to be applied to targeted therapy of GC. As a membranous vesicle, EVs can encapsulate specific biomolecules, participating in intracellular communications. Current studies have elucidated that circRNAs can be wrapped by EVs. Like circRNAs in cells, circRNAs exist in homeostasis in exocrine under normal conditions. In diseased conditions, however, homeostasis in exocrine is off, as the balance of intracellular circRNAs shifts. By modifying the number of EVs and specific circRNA levels in EVs, the content of circRNAs in receptor cells can be regulated which restores the homeostasis of the intracellular circRNAs, amending the downstream signaling pathways, such as miRNAs, so that the biological behaviors of receptor cells can be improved. These circRNAs play various roles in different periods of GC development through specific pathways. Compared with traditional therapies, these therapies using tissue and developmental stage specific circRNAs as targets for drugs or drug treatments act on particular targets, obtaining a more targeted way, which can not only help prevent side effects but also conduct individualized treatment for the distinct conditions of individual disease.

Correlation between circRNAs expression levels and prognosis in patients with gastric cancer
============================================================================================

Recent studies have demonstrated that circRNAs not only affect the proliferation abilities of GC cells through regulating signal pathways and are related to different phenotypes, but also have the ability to predict the relapse free survival and overall survival of patients[@B76]. At present, biomarkers circPVT1, circ_100269, etc have been discovered in GC tissues to be associated with GC prognosis.

CircPVT1 encoded by PVT1 gene was up-regulated in GC tissues, and was illustrated to be a proliferative factor for GC in further cell experiments[@B77]. Analyzing the expression of circPVT1 in 187 GC patients and their 85 months follow-up results, researchers revealed that circPVT1 was an independent prognostic biomarker for the overall survival (OS) rate and disease-free survival (DFS) of patients with GC[@B77]. Another study indicated that circ_100269 was associated with GC cell proliferation[@B78]. *In vitro* cell experiment, expression of circ_100269 was found to be inversely correlated with miR-630 and a direct interaction exist between them according to the results of dual-luciferase assay[@B78]. What\'s more, overexpressed circRNA_100269 could repress cell proliferation[@B78]. In tissue experiment, circRNA_100269 was downregulated in GC tissues, meanwhile demonstrating a prominent predictive function for the overall survival of the patients [@B78]. All these findings suggested that circPVT1 and circRNA_100269 might not only play roles in the treatments of GC, but also be prognostic biomarkers for GC. Correlation between circRNAs and the prognosis of gastric cancer is shown in Table [3](#T3){ref-type="table"}.

Conclusion
==========

CircRNA, as a kind of tissue specific RNA with more stable structure than linear RNAs play vital roles in physiological processes, pathological processes and disease progression. This review summarized CircRNAs and its relationship with gastric cancer from multi-angle of view. Evidence-based results suggests that circRNAs are not only involved in the regulation of the biological behaviors of GC cells, such as proliferation, invasion, migration and EMT, but also related to the clinicopathological features of GC patients, such as tumor differentiation, TNM stage and metastasis. CircRNAs are also regarded as biomarkers for early diagnosis and prognosis of GC. CircRNAs participating in the development of GC have the potential as novel targets for the individualized treatment of GC. The molecular mechanism explaining the correlations between circRNAs and GC is a emerging field and further researches are in demand. Furthermore, as biomarkers for the diagnosis and prognosis of GC, it\'s of vital significance to further screen and verify circRNAs in tissues and plasma.
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###### 

CircRNAs associated with gastric cancer

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Role             CircRNAs           circRNA ID         Gene\      Chromosome   Best\        Function        Mechanism                                                                               Year   Ref.
                                                         Symbol                  transcript                                                                                                                  
  ---------------- ------------------ ------------------ ---------- ------------ ------------ --------------- --------------------------------------------------------------------------------------- ------ ------
  **Oncogene**     circPVT1           /                  PVT1       chr8         /            proliferation   as a sponge for members of the miR-125 family                                           2017   77

                   hsa_circ_0047905   hsa_circ_0047905   SERPINB5   chr18        NM_002639    proliferation   positively correlated with their parental gene mRNA                                     2017   75

                   circNRIP1                             NRIP1      chr21        NM_003489    proliferation   as a sponge for members of the miR-149-5p to affect the                                 2019   47

                                                                                              migration       expression level of AKT1                                                                       

                                                                                              invasion                                                                                                       

                   circDLST           has_circ_0032627   DLST       chr14        NM_001933    proliferation   as a sponge for members of the miR-502-5p to activate                                   2019   46

                                                                                              invasion        the NRAS/MEK1/ERK1/2 signaling                                                                 

                   hsa_circ_0067997   hsa_circ_0067997   FNDC3B     chr3         NM_022763    invasive        regulating miR-515-5p/XIAP axis                                                         2019   48

                   circ-ERBB2         /                  /          /            /            proliferation   sponged miR-503 and miR-637                                                             2019   54

                                                                                              apoptosis                                                                                                      

                                                                                              migration                                                                                                      

                                                                                              invasion                                                                                                       

                   circRNA_001569     /                  /          /            /            apoptosis       suppressing the expression of miR-145, which was mediated by NR4A2                      2019   50

                   circPDSS1          /                  /          /            /            apoptosis       regulating miR-186-5p and NEK2,                                                         2019   49

                   circ_DONSON        /                  DONSON     chr21        /            proliferation   recruiting the NURF complex to initiate SOX4 expression                                 2019   55

                                                                                              migration                                                                                                      

                                                                                              invasion                                                                                                       

                                                                                              apoptosis                                                                                                      

  **Suppressor**   circRNA_100269     /                  LPHN2      chr1         /            proliferation   the target miRNA was miR-630                                                            2017   78

                   circ-104916        /                  /          /            /            proliferation   downregulated E-cadherin,upregulated,N-cadherin, Vimentin and Slug                      2017   56

                                                                                              migration                                                                                                      

                                                                                              invasion                                                                                                       

                                                                                              metastasis                                                                                                     

                   hsa_circ_0000096   hsa_circ_0000096   HIAT1      chr1         NM_033055    proliferation   regulating cyclin D1, CDK6, MMP-2 and MMP-9                                             2017   74

                   migration                                                                                                                                                                                 

                   circLARP4          /                  LARP4      chr12        /            invasion        sponging miR-424 and upregulating LATS1 gene                                            2017   57

                   circ-ZFR           /                  /          /            /            proliferation   sponging miR-130a/miR-107 and regulating PTEN                                           2018   25

                                                                                              apoptosis                                                                                                      

                   hsa_circ_0001368   hsa_circ_0001368   KLHL24     chr3         NM_017644    proliferation   miR-6506-5p/FOXO3 axis                                                                  2019   58

                                                                                              invasion                                                                                                       

                   circFAT1 (e2)      hsa_circ_0001461   FAT1       chr4         NM_005245    proliferation   regulating the miR-548g/RUNX1 axis in the cytoplasm and targeting YBX1 in the nucleus   2019   59

                                                                                              migration                                                                                                      

                                                                                              invasion                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Diagnostic efficiency of circRNAs for gastric cancer

  CircRNAs                             Sample   Expression        AUC     Se      Sp      cut-off   Year   Ref.
  ------------------------------------ -------- ----------------- ------- ------- ------- --------- ------ ------
  hsa_circ_0047905                     tissue   up-regulation     0.850   0.743   0.877   /         2017   75
  hsa_circ_0138960                     tissue   up-regulation     0.647   0.677   0.645   /                
  hsa_circRNA_7690-15                  tissue   up-regulation     0.681   0.679   0.613   /                
  hsa_circ_102958                      tissue   up-regulation     0.740   /       /       /         2019   60
  hsa_circ_002059                      tissue   Down-regulation   0.730   0.810   0.620   12.900    2015   71
  hsa_circ_0000096                     tissue   Down-regulation   0.820   0.880   0.560   12.900    2017   74
  hsa_circ_0001649                     tissue   Down-regulation   0.834   0.711   0.816   0.227     2017   11
  hsa_circ_0001895                     tissue   Down-regulation   0.792   0.678   0.857   9.530     2017   67
  hsa_circ_0014717                     tissue   Down-regulation   0.696   0.594   0.813   12.140    2017   10
  hsa_circ_0003159                     tissue   Down-regulation   0.750   0.852   0.565   12.310    2017   69
  hsa_circ_0006633                     tissue   Down-regulation   0.741   0.600   0.810   8.170     2017   68
  hsa_circ_0000190                     tissue   Down-regulation   0.750   0.721   0.683   6.830     2017   66
  hsa_circ_0000190                     plasma   Down-regulation   0.600   0.414   0.875   3.070            
  hsa_circ_0000181                     tissue   Down-regulation   0.756   0.539   0.852   9.400     2017   72
  hsa_circ_0000181                     plasma   Down-regulation   0.582   0.990   0.206   7.270            
  hsa_circ_0000745                     plasma   Down-regulation   0.683   0.855   0.450   /         2017   12
  hsa_circ_0001017, hsa_circ_0061276   plasma   Down-regulation   0.966   0.955   0.957   /         2018   70
  hsa_circ_0000467                     plasma   up-regulation     0.790   0.705   0.648   /         2019   76

###### 

CircRNAs and gastric cancer prognosis

  CircRNAs         Sample   Expression        Number of cases   Survival   Follow-up (months)   HR (95%CI)           Year   Ref.
  ---------------- -------- ----------------- ----------------- ---------- -------------------- -------------------- ------ ------
  circPVT1         tissue   Up-regulation     187               OS         83                   0.600(0.400-0.880)   2017   77
  ciRS-7           tissue   Up-regulation     102               OS         60                   2.110(0.940-3.890)   2018   73
  ciRS-7           tissue   Up-regulation     154               OS         60                   2.630(1.230-5.550)          
  circRNA_100269   tissue   Down-regulation   112               OS         50                   0.600(0.350-1.020)   2017   78
  circLARP4        tissue   Down-regulation   80                OS         108                  0.502(0.240-1.048)   2017   57
  circPVT1         tissue   Up-regulation     187               DFS        85                   0.490(0.330-0.720)   2017   77
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